Neuroone Medical Technologies is trading 10.09% down at $1.78, after declining from the August 27 close of $1.98, with no clear company-specific catalyst identified.
- The August 27 announcement reported successful large-animal StereoCED procedures and progress toward human investigations, rather than adverse news.
- Broader markets are modestly higher, so the move is not clearly explained by overall market weakness.